NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$36.19
-11.23 (-23.68%)
Close of Nov 06, 2026 · end-of-day data
AMN 8-K filings in 2024
Every material Form 8-K Amn Healthcare Services filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AMN Healthcare's Chairman, Douglas D. Wheat, notified the company on November 9, 2024, that he will not stand for re-election at the 2025 annual meeting and will retire from the board then. The filing says his decision is not due to any disagreement with the company or board on operations, policies or practices. The board has named director Mark G. Foletta, on the board since 2012, as the next Chairman effective after that meeting, subject to his re-election.
Douglas D. Wheat notified the company on November 9, 2024, that he will not stand for re-election at the 2025 annual meeting.
Wheat's retirement is not tied to any disagreement with the company or board, according to the filing.
On November 11, 2024, the board appointed Mark G. Foletta, a director since 2012, as Chairman effective after the 2025 annual meeting, subject to his re-election.
AMN Healthcare reported third quarter 2024 revenue of $687.5 million, down 19% from a year earlier, with GAAP diluted EPS of $0.18 versus $1.39 and adjusted diluted EPS of $0.61 versus $1.97. The company guided fourth quarter revenue to $685 million to $705 million, 14% to 16% below the prior year, and separately amended its credit agreement to allow a higher maximum net leverage ratio through December 31, 2025.
Q3 2024 revenue was $687.5 million, down 19% from $853.5 million in Q3 2023; net income was $7.0 million versus $53.2 million
Fourth quarter 2024 guidance: revenue of $685 million to $705 million and operating margin of 1.8% to 2.5%
Fourth Amendment dated November 5, 2024 raises the maximum Consolidated Net Leverage Ratio to 4.50 to 1.00 for December 31, 2024 through December 31, 2025, reverting to 4.00 to 1.00 afterward
Net leverage ratio was 2.8 to 1.0 at September 30, 2024, and the company reduced debt by $60 million in the quarter
AMN Healthcare appointed Brian Scott, its former CFO and Chief Accounting Officer from 2011 to 2021, as Chief Financial Officer and Chief Operating Officer, effective November 21, 2024. The appointment follows the announced departure of CFO Jeffrey Knudson, effective November 8, 2024, and places Scott in charge of finance and enterprise operating functions.
Brian Scott becomes CFO/COO on November 21, 2024, reporting to CEO Cary Grace.
Jeffrey Knudson leaves the CFO role effective November 8, 2024, to join a private company outside healthcare.
Scott's annualized base salary is $630,000, with a target bonus of 100% of base salary from 2025.
Scott receives a one-time equity grant valued at $2,000,000 on December 15, 2024, and a target 2025 LTIP award of $2,000,000.
AMN Healthcare said Chief Financial Officer Jeffrey Knudson will leave his role on November 8, 2024, to join a private company outside the healthcare staffing industry. The company expects to name a new leader for an expanded CFO/COO position before his departure, and it reaffirmed its third quarter 2024 guidance, which matters to shareholders because the CFO transition comes ahead of the company's next earnings report.
Jeffrey Knudson steps down as CFO effective November 8, 2024, after three years in the role
AMN expects to announce a new leader for an expanded CFO/COO position before Knudson's departure
Third quarter 2024 financial guidance reaffirmed; results are scheduled for release on November 7, 2024
AMN Healthcare reported second-quarter 2024 revenue of $741 million, down 25% from a year earlier, with GAAP diluted EPS of $0.42 compared with $1.55 in the second quarter of 2023. Its third-quarter outlook projects revenue of $660 million to $680 million, 20% to 23% below the prior year, which signals that the year-over-year decline is expected to continue.
Q2 2024 revenue was $741 million, down 25% year over year and 10% from the first quarter.
GAAP diluted EPS was $0.42 versus $1.55 a year earlier; adjusted diluted EPS was $0.98 versus $2.38.
Third-quarter 2024 revenue guidance is $660 million to $680 million, 20% to 23% lower than the prior year.
Operating cash flow was $100 million in the quarter, and the company reduced debt by $80 million; total debt was $1.195 billion at June 30, 2024.
AMN Healthcare's board increased its size from eight to nine and elected James H. Hinton as a director, effective July 22, 2024. The board determined he is independent under NYSE rules, and he joins two board committees. The change is a board composition update and does not involve a change in the company's operations or results.
Board voted July 2, 2024 to expand from eight to nine members and elect James H. Hinton
Hinton's appointment is effective July 22, 2024, with a term expiring at the 2025 Annual Meeting of Shareholders
Hinton will receive restricted stock units with an aggregate grant date fair value of approximately $127,500
He will also receive a pro-rata cash retainer starting at $17,363.76, plus a $22,500 quarterly retainer from Q4 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amn Healthcare Services filing is on SEC EDGAR ↗. 8-K briefs of other companies →